Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442720 + Pembrolizumab or Adagrasib in Advanced Malignancies
NCT04418661Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of vociprotafib in solid tumor, non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Jun 2020; status: terminated.
02
Drugs
vociprotafib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04418661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418661.